

# US Healthcare Sector M&A & Valuation TLDR - 2025-12-17

*US Healthcare Sector*

*Generated on 2025-12-17*

*CONFIDENTIAL - FOR INTERNAL USE ONLY*

## 1. 30-Second TL;DR

---

- The US Healthcare sector is experiencing cautious optimism, with growth in mental health, biotech, and digital health.
- Valuation multiples show an average EV/EBITDA of 18.5x, with biotech at 25.1x and digital health at 28.5x, indicating strong investor interest.
- Key drivers include technological advancements and increased investment, while regulatory scrutiny and economic uncertainties pose challenges.

## 2. 1-Minute TL;DR

---

- The US Healthcare sector is navigating a landscape of cautious optimism, particularly in mental health and biotech, driven by technological advancements and evolving consumer needs.
- Valuation multiples as of Q2 2025 average 18.5x EV/EBITDA, with biotech at 25.1x and digital health at 28.5x, reflecting high growth potential.
- Key market drivers include strong investment in AI and telehealth, while headwinds consist of regulatory scrutiny and economic uncertainties, particularly with the expiration of ACA subsidies.
- Recent M&A activity includes Cycle Pharmaceuticals acquiring Applied Therapeutics and Mirum Pharmaceuticals pursuing Bluejay Therapeutics, indicating a robust deal pipeline.

## 3. 2-Minute TL;DR

---

- The US Healthcare sector is characterized by cautious optimism, particularly in mental health, biotech, and digital health. Companies are focusing on innovative therapies, with the pharmaceutical sector stable and the biotech subsector experiencing significant growth, especially in mRNA technology.
- Valuation multiples for the sector average 18.5x EV/EBITDA, with notable variations: pharmaceuticals at 15.3x, biotech at 25.1x, medical devices at 12.8x, healthcare services at 14.7x, and digital health at 28.5x. This indicates a premium for high-growth areas like biotech and digital health.

# US Healthcare Sector M&A & Valuation TLDR - 2025-12-17

## *US Healthcare Sector*

- Key drivers include technological advancements in AI and telehealth, alongside strong venture capital investments. However, regulatory scrutiny and economic uncertainties, particularly related to healthcare costs, pose risks.
- Recent M&A activity includes Cycle Pharmaceuticals' acquisition of Applied Therapeutics and Mirum Pharmaceuticals' pursuit of Bluejay Therapeutics, reflecting a strong deal pipeline projected to generate approximately \$30 million in fees.
- Stakeholder impacts from insider share acquisitions, such as MAIA Biotechnology's leadership buying shares, signal confidence but also potential dilution risks for existing shareholders. The market reaction has been positive, with analysts noting that insider purchases often indicate undervaluation.
- Overall, the healthcare sector is poised for growth, with opportunities in mental health, AI, and data management, while investors should remain vigilant about regulatory changes and market dynamics.